FDAnews Drug Daily Bulletin

Eli Lilly’s antidepressant Cymbalta will remain patent protected until December 2013, now that the company has snagged an additional six months U.S. marketing exclusivity by conducting FDA-requested pediatric trials. But the company’s multi-billion dollar drug won’t see a sales boost from young patients, as negative study outcomes persuaded Lilly not to seek a pediatric indication for Cymbalta, the drugmaker said.
Washington Drug Letter